Literature DB >> 2731107

Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases.

J C Dalrymple1, P Bannatyne, P Russell, H J Solomon, M H Tattersall, K Atkinson, J Carter, P Duval, P Elliott, M Friedlander.   

Abstract

The rate and clinical features of patients admitted to King George V Hospital with extraovarian peritoneal serous papillary carcinoma during a 9-year period were reviewed. In this time, 31 of 236 (13%) patients with an initial diagnosis of invasive serous ovarian carcinoma fulfilled the surgicopathologic criteria for this entity. All patients had disseminated tumor equivalent to ovarian Stage III and IV disease (International Federation of Gynecology and Obstetrics [FIGO]) and with predominantly high-grade neoplasms. They were managed by surgical exploration, tumor debulking where possible, and postoperative chemotherapy. A comparison with a contemporaneous series of 139 patients with primary epithelial ovarian carcinoma matched for stage and grade of disease and managed similarly showed no difference in actuarial survival. The median survival times were 11.3 months for patients with extraovarian serous papillary carcinomas and 13.5 months for patients with equivalent primary ovarian neoplasms. The features of the disease and the treatment regimens used are discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2731107     DOI: 10.1002/1097-0142(19890701)64:1<110::aid-cncr2820640120>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels.

Authors:  H R Rosen; A C Rosen; J Preiser; M Stierer; M Klein; H Hanak
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

2.  Recent progress in the diagnosis and treatment of ovarian cancer.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  CA Cancer J Clin       Date:  2011-04-26       Impact factor: 508.702

Review 3.  Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms.

Authors:  Rosanny Espinal-Witter; Elliot L Servais; David S Klimstra; Michael D Lieberman; Rhonda K Yantiss
Journal:  Virchows Arch       Date:  2010-02-11       Impact factor: 4.064

4.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

5.  Gene expression patterns in ovarian carcinomas.

Authors:  Marci E Schaner; Douglas T Ross; Giuseppe Ciaravino; Therese Sorlie; Olga Troyanskaya; Maximilian Diehn; Yan C Wang; George E Duran; Thomas L Sikic; Sandra Caldeira; Hanne Skomedal; I-Ping Tu; Tina Hernandez-Boussard; Steven W Johnson; Peter J O'Dwyer; Michael J Fero; Gunnar B Kristensen; Anne-Lise Borresen-Dale; Trevor Hastie; Robert Tibshirani; Matt van de Rijn; Nelson N Teng; Teri A Longacre; David Botstein; Patrick O Brown; Branimir I Sikic
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

6.  The differential diagnosis of primary peritoneal papillary tumors.

Authors:  G Gitsch; U Tabery; W Feigl; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

7.  [Pathologic and anatomic evidence of peritoneal metastases].

Authors:  I Tischoff; A Tannapfel
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

Review 8.  The cell of origin of ovarian epithelial tumours.

Authors:  Louis Dubeau
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

9.  Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact?

Authors:  Marc T Goodman; Yurii B Shvetsov
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

10.  Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.

Authors:  Aasia Saleemuddin; Ann K Folkins; Leslie Garrett; Judy Garber; Michael G Muto; Christopher P Crum; Shelley Tworoger
Journal:  Gynecol Oncol       Date:  2008-08-21       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.